These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

761 related articles for article (PubMed ID: 18445827)

  • 1. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
    Punglia RS; Burstein HJ; Winer EP; Weeks JC
    J Natl Cancer Inst; 2008 May; 100(9):642-8. PubMed ID: 18445827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
    Rae JM; Drury S; Hayes DF; Stearns V; Thibert JN; Haynes BP; Salter J; Sestak I; Cuzick J; Dowsett M;
    J Natl Cancer Inst; 2012 Mar; 104(6):452-60. PubMed ID: 22395643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
    Gurwitz D; Newman W
    J Natl Cancer Inst; 2008 Sep; 100(18):1331; author reply 1332-4. PubMed ID: 18780871
    [No Abstract]   [Full Text] [Related]  

  • 4. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
    Regan MM; Leyland-Jones B; Bouzyk M; Pagani O; Tang W; Kammler R; Dell'orto P; Biasi MO; Thürlimann B; Lyng MB; Ditzel HJ; Neven P; Debled M; Maibach R; Price KN; Gelber RD; Coates AS; Goldhirsch A; Rae JM; Viale G;
    J Natl Cancer Inst; 2012 Mar; 104(6):441-51. PubMed ID: 22395644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
    Chlebowski RT; Col N
    J Natl Cancer Inst; 2008 Sep; 100(18):1331-2; author reply 132-3. PubMed ID: 18780870
    [No Abstract]   [Full Text] [Related]  

  • 6. A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients?
    Hayes DF; Stearns V; Rae J; Flockhart D;
    J Natl Cancer Inst; 2008 May; 100(9):610-3. PubMed ID: 18445818
    [No Abstract]   [Full Text] [Related]  

  • 7. Tailoring adjuvant endocrine therapy for postmenopausal breast cancer: a CYP2D6 multiple-genotype-based modeling analysis and validation.
    Yu KD; Huang AJ; Shao ZM
    PLoS One; 2010 Dec; 5(12):e15649. PubMed ID: 21187922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.
    Goetz MP; Knox SK; Suman VJ; Rae JM; Safgren SL; Ames MM; Visscher DW; Reynolds C; Couch FJ; Lingle WL; Weinshilboum RM; Fritcher EG; Nibbe AM; Desta Z; Nguyen A; Flockhart DA; Perez EA; Ingle JN
    Breast Cancer Res Treat; 2007 Jan; 101(1):113-21. PubMed ID: 17115111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.
    Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
    J Clin Oncol; 2005 Aug; 23(22):5178-87. PubMed ID: 15998905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
    Baumann CK; Castiglione-Gertsch M
    Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen.
    Okishiro M; Taguchi T; Jin Kim S; Shimazu K; Tamaki Y; Noguchi S
    Cancer; 2009 Mar; 115(5):952-61. PubMed ID: 19156902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.
    Schroth W; Goetz MP; Hamann U; Fasching PA; Schmidt M; Winter S; Fritz P; Simon W; Suman VJ; Ames MM; Safgren SL; Kuffel MJ; Ulmer HU; Boländer J; Strick R; Beckmann MW; Koelbl H; Weinshilboum RM; Ingle JN; Eichelbaum M; Schwab M; Brauch H
    JAMA; 2009 Oct; 302(13):1429-36. PubMed ID: 19809024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics of Aromatase Inhibitors in Endocrine Responsive Breast Cancer: Lessons Learnt from Tamoxifen and CYP2D6 Genotyping.
    Baatjes KJ; Conradie M; Apffelstaedt JP; Kotze MJ
    Anticancer Agents Med Chem; 2017; 17(13):1805-1813. PubMed ID: 28403774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy.
    Kiyotani K; Mushiroda T; Sasa M; Bando Y; Sumitomo I; Hosono N; Kubo M; Nakamura Y; Zembutsu H
    Cancer Sci; 2008 May; 99(5):995-9. PubMed ID: 18294285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy.
    Thompson AM; Johnson A; Quinlan P; Hillman G; Fontecha M; Bray SE; Purdie CA; Jordan LB; Ferraldeschi R; Latif A; Hadfield KD; Clarke RB; Ashcroft L; Evans DG; Howell A; Nikoloff M; Lawrence J; Newman WG
    Breast Cancer Res Treat; 2011 Jan; 125(1):279-87. PubMed ID: 20809362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy.
    Damodaran SE; Pradhan SC; Umamaheswaran G; Kadambari D; Reddy KS; Adithan C
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):75-81. PubMed ID: 22623212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.
    Jin Y; Desta Z; Stearns V; Ward B; Ho H; Lee KH; Skaar T; Storniolo AM; Li L; Araba A; Blanchard R; Nguyen A; Ullmer L; Hayden J; Lemler S; Weinshilboum RM; Rae JM; Hayes DF; Flockhart DA
    J Natl Cancer Inst; 2005 Jan; 97(1):30-9. PubMed ID: 15632378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Simulation Study to Compare the Treatment Effect of Tamoxifen by CYP2D6 Genotypes and Third-Generation Aromatase Inhibitors.
    Park GC; Jung JA; Bae KS; Lim HS
    J Clin Pharmacol; 2017 Sep; 57(9):1088-1096. PubMed ID: 28369967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.
    Fleeman N; Martin Saborido C; Payne K; Boland A; Dickson R; Dundar Y; Fernández Santander A; Howell S; Newman W; Oyee J; Walley T
    Health Technol Assess; 2011 Sep; 15(33):1-102. PubMed ID: 21906462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
    ; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
    N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.